Pharmaceutical giant accelerates domestic production expansion amid tariff pressures and supply chain reshoring initiatives.

North Chicago, Illinois, United States: AbbVie announced on February 23, 2026, a $380 million investment to construct two new active pharmaceutical ingredient (API) manufacturing facilities at its North Chicago, Illinois campus, expanding domestic production capacity for neuroscience and obesity medicines. Construction at the new facilities will commence in spring 2026, with full operational readiness targeted for 2029. The investment forms part of AbbVie's broader strategy to scale up domestic manufacturing in response to the Trump administration's 100% tariff on branded pharmaceutical drugs imposed in October 2025, which applies only to producers who had not broken ground on U.S. manufacturing plants prior to the tariff implementation. The new facilities will integrate advanced manufacturing technologies and artificial intelligence to support production of future pipeline medicines, with API production representing one of the most complex steps in pharmaceutical manufacturing. AbbVie plans to hire 300 personnel in North Chicago, including engineers, scientists, manufacturing operators, and laboratory technicians. This investment supplements a previously announced $195 million expansion at the same North Chicago site and contributes to AbbVie's decade-long $100 billion commitment to U.S.-based research and development announced in January 2026.

According to Robert A. Michael, Chairman and Chief Executive Officer, AbbVie, “This milestone demonstrates further progress against our $100 billion commitment to U.S. R&D and capital investments over the next decade. By strengthening our U.S. manufacturing capabilities, we are well-positioned to support our investment in innovation and enhance our ability to deliver next-generation medicines to patients.”

According to TechSci Research, AbbVie's substantial API manufacturing expansion exemplifies the pharmaceutical industry's strategic response to escalating U.S. trade protectionism and heightened emphasis on supply chain sovereignty. The timing of the investment immediately following the 100% branded drug tariff implementation demonstrates proactive regulatory navigation to maintain market access advantages. By establishing domestic API production capabilities for high-value neuroscience and obesity therapeutics, AbbVie insulates its fastest-growing product portfolios from import disruptions while potentially qualifying for favorable regulatory treatment under emerging domestic manufacturing incentives. The integration of advanced manufacturing technologies and AI positions these facilities as next-generation production assets capable of supporting complex molecular entities and biologics. This investment trend toward pharmaceutical reshoring is likely to accelerate across the industry, particularly for companies with significant exposure to import-dependent supply chains, potentially reshaping global pharmaceutical manufacturing geography and creating long-term competitive advantages for firms that execute capacity expansions swiftly.